Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?

Zang, Rongyu; Zhu, Jianqing

doi:10.3802/jgo.2019.30.e116

Cited by 11 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, GOG-0213 did not show a survival benefit of SCR followed by chemotherapy compared with chemotherapy alone [5]. However, the patient selection criteria are different from the other 2 trials, which is only deemed by the investigator to be amenable to complete gross resection [6]. While, DESKTOP III trial selects possibly resectable patients by using the AGO model that includes 3 factors: 1) complete resection at first surgery, 2) good performance status, and 3) absence of ascites.…”

Section: Introducitonmentioning

confidence: 99%

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography-computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles

show abstract

Section: Introducitonmentioning

confidence: 99%

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…For patients who experience partially platinumsensitive relapse, which is defined as progression within 6 to 12 months after the last platinum-based chemotherapy treatment, the treatment has not yet been standardized [3,[8][9][10][11], and there are certain factors that prevent some patients from re-using platinum-based chemotherapy shortly after the frontline platinum-based chemotherapy [12].…”

Section: Introductionmentioning

confidence: 99%

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

et al. 2021

View full text Add to dashboard Cite

Objective To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. Methods This was an open-label, single-arm and multicenter clinical trial. The ORR was the interim primary objective, and the DCR, AEs and QOL were the secondary objectives. The impact of factors on efficacy outcomes, the change trend of CA125 and the artificial platinum-free interval were exploratory endpoints. Results Totally, 115 patients were enrolled in this study and included in the ITT population. Moreover, 101 patients were included in the safety population. The median follow-up time was 4 months (IQR 2–6). In the ITT population, the confirmed ORR was 37.4% (95% CI, 28.4–46.4%), and the DCR was 65.2% (95% CI, 56.4–74.1%). The previous response status to platinum-based chemotherapy and baseline CA125 levels were significantly correlated with the ORR. The ORR was significantly higher in patients with a CA125 decrease after the first cycle than in the patients with a CA125 increase. The most common grade 3 or higher AE was hand-foot syndrome (3 [3.0%] of 101 patients). No statistically significant differences existed between the baseline and the postbaseline questionnaires. Conclusions For patients who experience platinum-resistant and platinum-refractory relapse, the use of PLD may be acceptable because of the associated satisfactory efficacy, low frequency of AEs and high patient QOL. Moreover, a low CA125 level at baseline and a reduction in CA125 after the first cycle are predictive factors for satisfactory efficacy.

show abstract

“…For patients with partially platinum-sensitive relapse, which is de ned as progression within 6 to 12 months after the last platinum-based chemotherapy treatment, the treatment has not been standardized [3,[8][9][10][11]and there are some factors that prevent some patients from re-using platinum-based chemotherapy shortly after the frontline platinum-based chemotherapy [12]. Therefore, this clinical trial was aimed to evaluate the e cacy and safety of PLD in treating patients with platinumrefractory, platinum-resistant and partially platinum-sensitive relapse in China.…”

Section: Introductionmentioning

confidence: 99%

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Yuan

Zhang

Cao

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Objective To evaluate the efficacy and safety of PLD in treating of in patients with epithelial ovarian, tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. Methods This was an open-label, single-arm and multicenter clinical trial. ORR was the interim primary objective and DCR, AEs and QOL were the secondary objectives. The impact of factors on the efficacy outcomes, the change trend of CA125 and the artificial platinum-free interval were exploratory endpoints. Results Totally, 115 patients were enrolled in this study and included in the ITT. Moreover, 101 patients were included in the safety analysis. The median follow-up time was 4 months (IQR 2–6). In ITT, the confirmed ORR was 37.4% (95%CI, 28.4%-46.4%), and the DCR was 65.2% (95%CI, 56.4%-74.1%). The previous response status to platinum-based chemotherapy and baseline CA125 levels were statistically correlated with the ORR. The ORR was significantly higher in the patients with a CA125 decrease after the first cycle than in the patients with a CA125 increase. The most common grade 3 or higher AE was hand-foot syndrome (3 [3.0%] of 101 patients). No statistically significant differences existed between the baseline and the postbaseline questionnaires. Conclusions For patients with platinum-resistant and platinum refractory relapse, the use of PLD may be a favorite choice because of the associated satisfactory efficacy, low frequency of AEs and high patient QOL. Moreover, a lower CA125 level at baseline and a reduction in CA125 after the first cycle are predictive factors for a better efficacy.

show abstract

Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer?

Abstract: Which patients benefit from secondary cytoreductive surgery in recurrent ovarian cancer? ► See the article "The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients" in volume 30, e100.

Cited by 11 publications

References 12 publications

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer

Contact Info

Product

Resources

About